PMC:7291971 / 85080-85465 JSONTXT

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T1684","span":{"begin":0,"end":8},"obj":"SP_10"},{"id":"T1685","span":{"begin":9,"end":14},"obj":"PR:000000125"},{"id":"T1686","span":{"begin":19,"end":24},"obj":"SP_6;NCBITaxon:9606"},{"id":"T1687","span":{"begin":146,"end":154},"obj":"SO:0000155"},{"id":"T1688","span":{"begin":174,"end":183},"obj":"GO:0010467"},{"id":"T1689","span":{"begin":187,"end":194},"obj":"NCBITaxon:562"},{"id":"T1690","span":{"begin":258,"end":266},"obj":"NCBITaxon:7742"},{"id":"T1691","span":{"begin":267,"end":272},"obj":"NCBITaxon:10239"},{"id":"T1692","span":{"begin":296,"end":303},"obj":"GO:0032991"},{"id":"T42","span":{"begin":292,"end":317},"obj":"NCBITaxon:10239"},{"id":"T24440","span":{"begin":0,"end":8},"obj":"SP_10"},{"id":"T39744","span":{"begin":9,"end":14},"obj":"PR:000000125"},{"id":"T11149","span":{"begin":19,"end":24},"obj":"SP_6;NCBITaxon:9606"},{"id":"T17814","span":{"begin":146,"end":154},"obj":"SO:0000155"},{"id":"T90318","span":{"begin":174,"end":183},"obj":"GO:0010467"},{"id":"T4563","span":{"begin":187,"end":194},"obj":"NCBITaxon:562"},{"id":"T38822","span":{"begin":258,"end":266},"obj":"NCBITaxon:7742"},{"id":"T96822","span":{"begin":267,"end":272},"obj":"NCBITaxon:10239"},{"id":"T77113","span":{"begin":296,"end":303},"obj":"GO:0032991"}],"text":"SARS-CoV nsp14 and human RNA N7-methyltransferase (hRNMT) coding sequences were cloned in fusion with a N-terminus hexa-histidine tag in Gateway® plasmids. The proteins were expressed in E. coli and purified following previously described protocols [33,39]. Vaccinia virus capping enzyme (D1/D12 complex) and mRNA Cap 2′-O-methyltransferase (VP39) were purchased (New England Biolabs)."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T103","span":{"begin":25,"end":28},"obj":"Body_part"},{"id":"T104","span":{"begin":120,"end":129},"obj":"Body_part"},{"id":"T105","span":{"begin":160,"end":168},"obj":"Body_part"},{"id":"T106","span":{"begin":309,"end":313},"obj":"Body_part"}],"attributes":[{"id":"A103","pred":"fma_id","subj":"T103","obj":"http://purl.org/sig/ont/fma/fma67095"},{"id":"A104","pred":"fma_id","subj":"T104","obj":"http://purl.org/sig/ont/fma/fma82755"},{"id":"A105","pred":"fma_id","subj":"T105","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A106","pred":"fma_id","subj":"T106","obj":"http://purl.org/sig/ont/fma/fma67122"}],"text":"SARS-CoV nsp14 and human RNA N7-methyltransferase (hRNMT) coding sequences were cloned in fusion with a N-terminus hexa-histidine tag in Gateway® plasmids. The proteins were expressed in E. coli and purified following previously described protocols [33,39]. Vaccinia virus capping enzyme (D1/D12 complex) and mRNA Cap 2′-O-methyltransferase (VP39) were purchased (New England Biolabs)."}

{"project":"LitCovid-PubTator","denotations":[{"id":"1601","span":{"begin":120,"end":129},"obj":"Chemical"}],"attributes":[{"id":"A1601","pred":"tao:has_database_id","subj":"1601","obj":"MESH:D006639"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"SARS-CoV nsp14 and human RNA N7-methyltransferase (hRNMT) coding sequences were cloned in fusion with a N-terminus hexa-histidine tag in Gateway® plasmids. The proteins were expressed in E. coli and purified following previously described protocols [33,39]. Vaccinia virus capping enzyme (D1/D12 complex) and mRNA Cap 2′-O-methyltransferase (VP39) were purchased (New England Biolabs)."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T100","span":{"begin":0,"end":8},"obj":"Disease"},{"id":"T101","span":{"begin":258,"end":266},"obj":"Disease"}],"attributes":[{"id":"A100","pred":"mondo_id","subj":"T100","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A101","pred":"mondo_id","subj":"T101","obj":"http://purl.obolibrary.org/obo/MONDO_0002595"}],"text":"SARS-CoV nsp14 and human RNA N7-methyltransferase (hRNMT) coding sequences were cloned in fusion with a N-terminus hexa-histidine tag in Gateway® plasmids. The proteins were expressed in E. coli and purified following previously described protocols [33,39]. Vaccinia virus capping enzyme (D1/D12 complex) and mRNA Cap 2′-O-methyltransferase (VP39) were purchased (New England Biolabs)."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T442","span":{"begin":19,"end":24},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T443","span":{"begin":102,"end":103},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T444","span":{"begin":267,"end":272},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"}],"text":"SARS-CoV nsp14 and human RNA N7-methyltransferase (hRNMT) coding sequences were cloned in fusion with a N-terminus hexa-histidine tag in Gateway® plasmids. The proteins were expressed in E. coli and purified following previously described protocols [33,39]. Vaccinia virus capping enzyme (D1/D12 complex) and mRNA Cap 2′-O-methyltransferase (VP39) were purchased (New England Biolabs)."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T77784","span":{"begin":120,"end":129},"obj":"Chemical"},{"id":"T949","span":{"begin":160,"end":168},"obj":"Chemical"}],"attributes":[{"id":"A948","pred":"chebi_id","subj":"T77784","obj":"http://purl.obolibrary.org/obo/CHEBI_27570"},{"id":"A949","pred":"chebi_id","subj":"T949","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"}],"text":"SARS-CoV nsp14 and human RNA N7-methyltransferase (hRNMT) coding sequences were cloned in fusion with a N-terminus hexa-histidine tag in Gateway® plasmids. The proteins were expressed in E. coli and purified following previously described protocols [33,39]. Vaccinia virus capping enzyme (D1/D12 complex) and mRNA Cap 2′-O-methyltransferase (VP39) were purchased (New England Biolabs)."}

{"project":"2_test","denotations":[{"id":"32563813-17259217-29105596","span":{"begin":250,"end":252},"obj":"17259217"}],"text":"SARS-CoV nsp14 and human RNA N7-methyltransferase (hRNMT) coding sequences were cloned in fusion with a N-terminus hexa-histidine tag in Gateway® plasmids. The proteins were expressed in E. coli and purified following previously described protocols [33,39]. Vaccinia virus capping enzyme (D1/D12 complex) and mRNA Cap 2′-O-methyltransferase (VP39) were purchased (New England Biolabs)."}

{"project":"LitCovid-sentences","denotations":[{"id":"T559","span":{"begin":0,"end":155},"obj":"Sentence"},{"id":"T560","span":{"begin":156,"end":257},"obj":"Sentence"},{"id":"T561","span":{"begin":258,"end":385},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"SARS-CoV nsp14 and human RNA N7-methyltransferase (hRNMT) coding sequences were cloned in fusion with a N-terminus hexa-histidine tag in Gateway® plasmids. The proteins were expressed in E. coli and purified following previously described protocols [33,39]. Vaccinia virus capping enzyme (D1/D12 complex) and mRNA Cap 2′-O-methyltransferase (VP39) were purchased (New England Biolabs)."}

{"project":"MyTest","denotations":[{"id":"32563813-17259217-29105596","span":{"begin":250,"end":252},"obj":"17259217"}],"namespaces":[{"prefix":"_base","uri":"https://www.uniprot.org/uniprot/testbase"},{"prefix":"UniProtKB","uri":"https://www.uniprot.org/uniprot/"},{"prefix":"uniprot","uri":"https://www.uniprot.org/uniprotkb/"}],"text":"SARS-CoV nsp14 and human RNA N7-methyltransferase (hRNMT) coding sequences were cloned in fusion with a N-terminus hexa-histidine tag in Gateway® plasmids. The proteins were expressed in E. coli and purified following previously described protocols [33,39]. Vaccinia virus capping enzyme (D1/D12 complex) and mRNA Cap 2′-O-methyltransferase (VP39) were purchased (New England Biolabs)."}